MedTrace Logo

Iodine Status in Pregnancy and Associated Health Outcomes

NCT03552341 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 246

Last updated 2021-10-14

No results posted yet for this study

Summary

Iodine is a key micronutrient in the diet, essential for healthy growth, and is particularly important during pregnancy and breastfeeding when demands are increased to support the developing baby. Many people are thought to lack all the iodine they need, and this is a greater issue during and shortly after pregnancy when the body's iodine requirements are greatest. Iodine deficiency complications are potentially serious for both mother and child. Iodine deficiency can lead to thyroid enlargement, lower production of important hormones produced by the thyroid, pregnancy complications in the mother, and impaired growth and developmental problems in babies and children. This research will focus on providing an up-to-date estimate of how many pregnant women do not have enough iodine, and what different levels of iodine might mean in terms of health risks during pregnancy and for childhood development. The investigators will investigate how iodine levels vary over the course of pregnancy and lactation, how this is affected by diet, associated changes in thyroid size and function, and what levels of iodine are linked with greater risk of subsequent health problems. The research will take advantage of existing urine samples collected from mothers during pregnancy in the Born in Bradford birth cohort study, where the investigators also know of any adverse pregnancy outcomes, as well as any developmental problems for the baby and in early childhood.

Conditions

  • Cognitive Developmental Delay
  • Birth Weight

Interventions

OTHER

Maternal iodine status

Urinary iodine concentration during pregnancy at 26 weeks' gestation (Bord in Bradford study) and at 12, 26 and 36 weeks' gestation, 6, 18 and 30 weeks postpartum (Hiba longitudinal study). This is primarily in the form of Iodine to Creatinine ratio, to take spot urine volume into account. There is no intervention in this observational study.

Sponsors & Collaborators

  • Bradford Teaching Hospitals NHS Foundation Trust

    collaborator OTHER_GOV

  • University of Leeds

    lead OTHER

Principal Investigators

  • Darren C Greenwood, PhD · University of Leeds

  • Laura J Hardie, PhD · University of Leeds

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-01
Primary Completion
2019-03-31
Completion
2019-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03552341 on ClinicalTrials.gov